Assessment of prognosis with the total illness burden index for prostate cancer

@article{Litwin2007AssessmentOP,
  title={Assessment of prognosis with the total illness burden index for prostate cancer},
  author={Mark S. Litwin and Sheldon Greenfield and Eric P. Elkin and Deborah P. Lubeck and Jeanette M. Broering and Sherrie H Kaplan},
  journal={Cancer},
  year={2007},
  volume={109}
}
Among the most pressing challenges that face physicians who care for men with prostate cancer is evaluating the patient's potential for benefiting from treatment. Because prostate cancer often follows an indolent course, the presence and severity of comorbidities may influence the decision to treat the patient aggressively. The authors adapted the Total Illness Burden Index (TIBI) for use in decision‐making among men with prostate cancer at the time of the visit. 
Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer.
TLDR
The lack of a standardized and practical comorbidity assessment tool has limited the application of comorbridity to clinical decision making in this setting. Expand
Consideration of comorbidity in risk stratification prior to prostate biopsy
TLDR
These assessments were used to determine comorbidity and prognosis before prostate biopsy and the subsequent diagnosis of prostate cancer to identify those patients least likely to benefit from treatment. Expand
Comorbidity and competing risks for mortality in men with prostate cancer
TLDR
The authors sought to assess the competing risks of nonprostate cancer and prostate cancer mortality among men with differing Charlson comorbidity index scores and tumor risks. Expand
Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity.
  • K. Hoffman
  • Medicine
  • Seminars in radiation oncology
  • 2012
TLDR
Prostate cancer management decisions for older patients should be tailored based on an individual patient's health status, coexisting medical conditions, life expectancy, and tumor characteristics. Expand
Comorbidity assessment in localized prostate cancer: a systematic review protocol.
TLDR
This study is to review and summarize the methods and tools used to measure comorbidity in localized prostate cancer and to assess whether these tools are adequately validated and reliable for determining the impact of comorebidity on survival and treatment decisions for this disease. Expand
The importance of Charlsonovog comorbidity index in assessing multiyear survival of patients with prostate cancer
TLDR
CCI value significantly contributes to better assessment of the long-term survival and the selection of appropriate cancer therapy, and represents optimal balance between ease of use and prognostic capabilities. Expand
The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients
  • A. Vellekoop, S. Loeb
  • Medicine
  • Current Translational Geriatrics and Experimental Gerontology Reports
  • 2013
TLDR
Although screening has questionable benefit for elderly men with significant comorbidities, healthy men >75 years may benefit from definitive therapy and the use of nomograms and predictive tools for life expectancy is discussed. Expand
Assessment of comorbidities in surgical oncology outcomes
TLDR
It is shown that incorporation of comorbidity data in cancer registries facilitates surgical oncology research conduct with an objective to improve cancer care through better‐informed patient counseling and treatment planning. Expand
Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients
TLDR
Age, ACE-27 score and PMN act as independent prognostic factors for DOC in prostate cancer patients and can improve patient’s life expectancy prediction. Expand
Impact of comorbidity on health‐related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies
To improve and individualise estimates of treatment outcomes for men diagnosed with prostate cancer, we examined the impact of baseline comorbidity on health‐related quality of life (HRQL) outcomesExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
The impact of co-morbidity on life expectancy among men with localized prostate cancer.
TLDR
Each co-morbidity index tested is a highly significant predictor of mortality for patients dying of nonprostate cancer related causes after adjusting for age and Gleason score. Expand
Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer.
TLDR
The TIBI-P is a powerful measure of the impact of comorbid illness on the quality of life and functioning among patients with prostate cancer and may prove valuable in research on clinical and economic outcomes of prostate cancer. Expand
An Editorial Update: Should Benefits of Radical Prostatectomy Affect the Decision To Screen for Early Prostate Cancer?
TLDR
The New England Journal of Medicine recently published longer-term results of a landmark trial on radical prostatectomy, and the take on how they clarify treatment of early prostate cancer and the case for screening is taken. Expand
20-year outcomes following conservative management of clinically localized prostate cancer.
TLDR
The annual mortality rate from prostate cancer appears to remain stable after 15 years from diagnosis, which does not support aggressive treatment for localized low-grade prostate cancer. Expand
The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
TLDR
CaPSURE data confirm the usefulness of percent positive biopsies in risk assessment and they have further been used to validate multiple preoperative nomograms, and strongly affirm the necessity of patient reported quality of life assessment. Expand
Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.
TLDR
To estimate survival based on a competing risk analysis stratified by age at diagnosis and histologic findings for men diagnosed as having clinically localized prostate cancer and who were managed conservatively, a Retrospective cohort study is presented. Expand
Quality of life before death for men with prostate cancer: results from the CaPSURE database.
TLDR
Quality of life begins a steady and inexorable decline in thefinal 12 months of life in men with prostate cancer and increased attention to quality of life changes may provide new clinical opportunities to enhance quality of care in the final year of life. Expand
The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer.
OBJECTIVES To determine the accuracy of clinicians' predictions of life expectancy in patients with localized prostate cancer, when provided with information about age and comorbidity, and toExpand
Geriatric assessment and comorbidity.
TLDR
The ultimate aim would be to use comorbidity and comprehensive geriatric assessments prospectively in the older cancer patient to help predict the suitability and success of treatment with various antineoplastic modalities. Expand
The natural history of prostatic cancer
  • W. Whitmore
  • Medicine
  • Progress in clinical and biological research
  • 1984
TLDR
The relevance of the marked variability and unpredictability in the natural history of prostatic cancer thus revealed to treatment decisions and interpretations of the results of treatment in the aging host are indicated. Expand
...
1
2
3
4
...